Adagio Medical Holdings Inc. is a medical device company specializing in innovative catheter ablation technologies for the treatment of cardiac arrhythmias. It focuses on developing and commercializing advanced cryoablation systems that create contiguous, transmural lesions to address conditions such as paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes the iCLAS atrial ultra-low temperature cryoablation catheter and accessories, the vCLAS ventricular ultra-low temperature cryoablation catheter, and the Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings Inc. places its technologies on the EU market and advances clinical evaluations for broader applications in electrophysiology. Operating in the healthcare sector, it targets medical professionals and institutions seeking effective, single-shot ablation solutions to improve patient outcomes in rhythm management. Founded in 2011 and headquartered in Laguna Hills, California, Adagio Medical Holdings Inc. plays a key role in advancing next-generation therapies for complex cardiac conditions.